BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fish and Richardson
Accenture
Colorcon
Deloitte
Healthtrust
Dow
AstraZeneca
QuintilesIMS
Chinese Patent Office

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,180,125

« Back to Dashboard

Summary for Patent: 9,180,125
Title:Peripheral opioid receptor antagonists and uses thereof
Abstract: The present invention provides a compound of formula I: ##STR00001## wherein X.sup.-, R.sup.1, and R.sup.2 are as defined herein, and compositions thereof.
Inventor(s): Bazhina; Nataliya (Tappan, NY), Donato, III; George Joseph (Swarthmore, PA), Fabian; Steven R. (Barnegat, NJ), Lokhnauth; John (Fair Lawn, NJ), Megati; Sreenivasulu (New City, NY), Melucci; Charles (Highland Mills, NY), Ofslager; Christian (Newburgh, NY), Patel; Niketa (Lincoln Park, NJ), Radebaugh; Galen (Chester, NJ), Shah; Syed M. (Delray Beach, FL), Szeliga; Jan (Croton On Hudson, NY), Zhang; Huyi (Garnerville, NY), Zhu; Tianmin (Monroe, NY)
Assignee: Wyeth, LLC (Madison, NJ)
Application Number:14/322,382
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation; Use;

Drugs Protected by US Patent 9,180,125

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-003 Sep 27, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF OPIOID-INDUCED CONSTIPATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,180,125

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,247,425 Peripheral opioid receptor antagonists and uses thereof ➤ Subscribe
9,492,445 Peripheral opioid receptor antagonists and uses thereof ➤ Subscribe
9,724,343 Peripheral opioid receptor antagonists and uses thereof ➤ Subscribe
8,420,663 Peripheral opioid receptor antagonists and uses thereof ➤ Subscribe
8,455,644 Peripheral opioid receptor antagonists and uses thereof ➤ Subscribe
8,822,490 Peripheral opioid receptor antagonists and uses thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,180,125

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 619972 ➤ Subscribe
New Zealand 602667 ➤ Subscribe
New Zealand 591859 ➤ Subscribe
South Korea 20140091071 ➤ Subscribe
Mexico 2011003400 ➤ Subscribe
South Korea 20110060967 ➤ Subscribe
South Korea 101566675 ➤ Subscribe
Japan 2017101053 ➤ Subscribe
Japan 2015129144 ➤ Subscribe
Japan 5719773 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Baxter
Mallinckrodt
AstraZeneca
Cantor Fitzgerald
Citi
Merck
McKesson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot